Zydus Lifesciences gets USFDA’s final approval for Finasteride and Tadalafil Capsules

18 Mar 2024 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Finasteride and Tadalafil Capsules USP 5 mg/5 mg. (USRLD: ENTADFI). Zydus is the ‘first approved applicant’ for Finasteride and Tadalafil Capsules, 5 mg/5 mg, as defined in section 505(j)(5)(B)(v)(III) of the FD&C Act and therefore is eligible for 180 days of CGT exclusivity. 

Finasteride and Tadalafil is used to treat benign prostatic hyperplasia. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India. The group now has 392 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

916.55 -5.45 (-0.59%)
12-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1825.00
Dr. Reddys Lab 1318.75
Cipla 1325.25
Zydus Lifesciences 916.55
Lupin 2356.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×